832
Views
11
CrossRef citations to date
0
Altmetric
L-Norgestrel and Perimenopause

Why perimenopausal women should consider to use a levonorgestrel intrauterine system

Pages 659-661 | Received 18 Jan 2016, Accepted 08 Feb 2016, Published online: 01 Mar 2016

References

  • Chung SH, Kim TH, Lee HH, et al. Premenstrual syndrome and premenstrual dysphoric disorder in perimenopausal women. J Menopausal Med 2014;20:69–74.
  • Reed SD, Lampe JW, Qu C, et al. Premenopausal vasomotor symptoms in an ethnically diverse population. Menopause 2014;21:153–8.
  • Santoro N, Crawford SL, Lasley WL, et al. Factors related to declining luteal function in women during the menopausal transition. J Clin Endocrinol Metab 2008;93:1711–21.
  • Tanis BC. Oral contraceptives and the risk of myocardial infarction. Eur Heart J 2003;24:377–80.
  • Henshaw SK. Unintended pregnancy in the United States. Fam Plann Perspect 1998;30:24–9.
  • Fraser I. Non-contraceptive health benefits of intrauterine hormonal systems. Contraception 2010;82:396–403.
  • Fraser I. Added health benefits of the levonorgestrel contraceptive intrauterine system and other hormonal contraceptive delivery systems. Contraception 2013;87:273–9.
  • Gemzell-Danielsson K, Inki P, Heikimheimo O. Recent developments in the clinical use of the levonorgestrel-releasing intrauterine system. Acta Obstet Gynecol Scand 2011;90:1177–88.
  • Wildemeersch D, Janssens D, Andrade A. The Femilis LNG-IUS: contraceptive performance-an interim analysis. Eur J Contracept Reprod Health Care 2009;14:103–10.
  • Hampton NR, Rees MC, Lowe DG, et al. Levonorgestrel intrauterine system (LNG-IUS) with conjugated oral equine estrogen: a successful regimen for HRT in perimenopausal women. Hum Reprod 2005;20:2653–60.
  • Suvanto-Luukkonen E, Kauppila A. The levonorgestrel intrauterine system in menopausal hormone replacement therapy: five-year experience. Fertil Steril 1999;72:161–3.
  • Varila E, Wahlström T, Rauramo I. A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. Fertil Steril 2001;76:969–73.
  • Depypere HT, Hillard T, Erkkola R, et al. A 60-month non-comparative study on bleeding profiles with the levonorgestrel intrauterine system from late transition period to estrogen supplemented menopause. Eur J Obstet Gynecol Repod Biol 2010;153:176–80.
  • Wildemeersch D. Potential health benefits of continuous LNG-IUS combined with parenteral ERT for seamless menopausal transition and beyond – a commentary based on clinical experience. Gynecol Endocrinol 2013;29:569–73.
  • Santoro N, Teal S, Gavito C, et al. Use of a levonorgestrel-containing intrauterinen system with supplemental estrogen improves symptoms in perimenopausal women: a pilot study. Menopause 2015;12:1–7.
  • Nesse RE. Abnormal vaginal bleeding in perimenopausal women. Am Fam Physician 1989;40:185–92.
  • Rybo G. Population studies of menorrhagia. Res Clin Forums 1983;5:77–81.
  • Gallos ID, Shehmar M, Thangaratinam S, et al. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial levonorgestrel-releasing intrauterine system. Obstet Gynecol 2008;111:547–9.
  • Wildemeersch D, Pylyser K, De Wever N, Dhont M. Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: long-term follow-up. Maturitas 2007;57:210–13.
  • Reid R, Mukri F. Trends in number of hysterectomies performed in England for menorrhagia: examination of health episodestatistics, 1989 to 2002–3. Br Med J 2005;330:938–9.
  • Whitehead MI. General principles of administration of hormone replacement therapy: indications and contraindications, routes of administration, treatment schedules. In: Fraser IS, Jansen RPS, Lobo RA, Whitehead MI, eds. Estrogen and progestogensin clinical practice. London: Churchill Livingstone; 1998:667–86.
  • Furchgott RF, Zawadski JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373–6.
  • Hulley S, Grady D, Bush T, et al. Heart and Estrogen/progestin Replacement Study (HERS) Research Group Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J Am Med Assoc 1998;280:605–13.
  • Hammond CB. Women's concerns with hormone replacement therapy – compliance issues. Fertil Steril 1994;62:157S–60.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.